IN8bio 10-Q: Going Concern Warning With $14.0M Cash Lasting Only Through April 2027
INAB is trading near its 52-week low of $0.8 (5.0% above the low).
Summary
IN8bio's Q3 10-Q confirms a $4.6 million quarterly net loss and $14.0 million of cash that management says funds operations only through April 2027, with substantial doubt about going concern and the next capital dependent on INB-619 milestone-driven proceeds.
Key Events · Earnings and Guidance · INAB
-
Going Concern Doubt Restated
Management states $14.0 million of cash at September 30, 2026 will not fund projected operating expenses and capital expenditure requirements for at least 12 months from issuance, and is only expected to last through April 2027.
-
Q3 Net Loss Widens to $4.6M
Net loss was $4.6 million, or $0.24 per share, versus $3.9 million, or $0.85 per share, a year earlier; nine-month net loss was $14.5 million against a $155.6 million accumulated deficit.
-
Funding Levers Are Conditional
Up to roughly $20.1 million of additional gross proceeds from the December 2025 private placement depend on INB-619 preclinical data milestones, and only $2.8 million remained available under the ATM Program as of November 2, 2026.
-
Warrant Overhang Sits Above Market
Outstanding at September 30, 2026: 9,620,002 pre-funded warrants, 166,964 Series B warrants at a $13.50 strike and 828,863 Series C warrants at an $8.10 strike — the latter two far above the current share price.
Analysis · INAB · Life Sciences
The Q3 numbers were already out in this morning's 8-K, but the 10-Q is where the survival math becomes explicit: $14.0 million of cash against a $14.5 million nine-month operating loss, with management stating the balance will not fund operations for at least 12 months and only carries the company through April 2027. That leaves the December 2025 private placement's second tranche — up to roughly $20.1 million tied to INB-619 preclinical data — as the nearest real funding lever, alongside a $2.8 million ATM remainder that is itself capped by the baby-shelf limit on a public float under $75 million. Layered on top is a warrant stack of 9.6 million pre-funded plus 166,964 Series B and 828,863 Series C warrants, and a Nasdaq bid-price problem ($0.91 on November 2, 2026) that could force action before any of that capital arrives.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INAB was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $0.80 to $2.73. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.